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Abstract
Little is known about the protective role of inflammatory processes in modulating lipid metabolism in infection. Here we
report an intimate link between the innate immune response to infection and regulation of the sterol metabolic network
characterized by down-regulation of sterol biosynthesis by an interferon regulatory loop mechanism. In time-series
experiments profiling genome-wide lipid-associated gene expression of macrophages, we show a selective and coordinated
negative regulation of the complete sterol pathway upon viral infection or cytokine treatment with IFNc or b but not TNF,
IL1b, or IL6. Quantitative analysis at the protein level of selected sterol metabolic enzymes upon infection shows a similar
level of suppression. Experimental testing of sterol metabolite levels using lipidomic-based measurements shows a
reduction in metabolic output. On the basis of pharmacologic and RNAi inhibition of the sterol pathway we show
augmented protection against viral infection, and in combination with metabolite rescue experiments, we identify the
requirement of the mevalonate-isoprenoid branch of the sterol metabolic network in the protective response upon statin or
IFNb treatment. Conditioned media experiments from infected cells support an involvement of secreted type 1 interferon(s)
to be sufficient for reducing the sterol pathway upon infection. Moreover, we show that infection of primary macrophages
containing a genetic knockout of the major type I interferon, IFNb, leads to only a partial suppression of the sterol pathway,
while genetic knockout of the receptor for all type I interferon family members, ifnar1, or associated signaling component,
tyk2, completely abolishes the reduction of the sterol biosynthetic activity upon infection. Levels of the proteolytically
cleaved nuclear forms of SREBP2, a key transcriptional regulator of sterol biosynthesis, are reduced upon infection and IFNb
treatment at both the protein and de novo transcription level. The reduction in srebf2 gene transcription upon infection and
IFN treatment is also found to be strictly dependent on ifnar1. Altogether these results show that type 1 IFN signaling is
both necessary and sufficient for reducing the sterol metabolic network activity upon infection, thereby linking the
regulation of the sterol pathway with interferon anti-viral defense responses. These findings bring a new link between sterol
metabolism and interferon antiviral response and support the idea of using host metabolic modifiers of innate immunity as
a potential antiviral strategy.
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Introduction
Sterols and fatty acids are common intermediary metabolites
that play key roles in many biological pathways involved in
inflammatory diseases such as atherosclerosis and chronic heart
disease [1–4]. Significantly, mounting evidence shows a connec-
tion between innate immune signaling processes and the
regulation of sterol and fatty acid metabolism [5–8]. Specifically,
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cholesterol and its metabolites have been shown to alter
inflammatory mediator behavior [9–11], and conversely, innate
immune signaling has been shown to modulate the dynamics of
cholesterol transport, storage, and excretion [12–15]. Recent
studies have also begun to show that the perturbation of lipid
metabolism in a range of virally infected cells is a hallmark of
cellular changes associated with infection. For instance, studies
analyzing the consequences of human cytomegalovirus (CMV)
infection have shown that increases in the flux of the fatty acid
biosynthesis pathway are essential for optimal viral growth in
fibroblasts [16]. Further, Hepatitis C virus (HCV) has been shown
to co-opt the prenylation pathway to promote the efficient
replication of its genome [17–19]. More generally, a number of
other viruses, notably Measles, HIV, West Nile virus, and Dengue
virus, also have the ability to change cholesterol pathway gene
expression in a variety of cellular systems [20–24]. Whether the
effects of virus infection on the cholesterol pathway are directly
mediated by the pathogen or indirectly host-mediated mechanisms
is not known. From a therapeutic perspective, studies have also
shown that the pharmacological disruption of the cholesterol
metabolism by statins and other metabolic modifiers can result in
the inhibition of viral replication [25–32].
It is well documented that the cross-talk between immune
programs of macrophage activation and lipid homeostasis plays a
central part in chronic inflammatory diseases [33,34]. In particular
an anti-atherosclerosis transcriptional axis of PPARc regulating a
pathway of cholesterol efflux by inducing ABCA1 expression and
cholesterol removal from macrophages, via a transcriptional
cascade mediated by activated LXRa, has been reported [35].
Significantly, cellular metabolic, signaling, and regulatory pathways
also play a critical ‘‘collaborative’’ role in modulating immune
responses to infection [36]. In this context, Toll-like pathogen
recognition receptors, crucial to the initiation of innate immune
signaling, have recently been shown to regulate the expression of
key lipid-associated genes following bacterial infection. This occurs
due to microbial ligand activation of the IRF3 pathway, which
blocks the induction of LXR target genes such as ABCA1 and
inhibits cholesterol efflux from macrophages in an interferon
independent manner [5]. In this context, LXRa2/2 mice are
more susceptible to bacterial infection [37], further emphasizing the
importance of this pathway in the innate immune response. From a
viral perspective, an interferon-inducible protein ‘‘viperin’’ is known
to inhibit influenza A virus and HCV by disrupting the formation of
cholesterol-enriched lipid rafts, which act as attachment sites for
viral production [38,39]. Significantly, despite increasing numbers
of studies in this area, the question remains as to whether the
immune regulation of lipid pathways can also serve a role as part of
a protective anti-viral response. Indeed, in the context of host
protection pathways, it is not known whether a central immune
regulatory mechanism involving interferon response is directly or
indirectly required in modulating lipid metabolism in infection.
We are interested in elucidating the relationship between
transcriptional networks and immune regulatory pathways and
host-cell dependency mechanisms of pathogens, especially viruses,
as identifying host dependency mechanisms at the pathway level
provides a new molecular systems-level approach for understanding
viral pathogenesis, which can be harnessed as an anti-infective
strategy [40–42]. For many years, studies of virus-host interactions,
in particular for large DNA viruses, have proven invaluable in the
characterization of host cell molecular pathways and their
connectivity to the inflammatory response. Murine cytomegalovirus
(mCMV), which has a large double-stranded DNA genome,
represents one of the few model organisms studied in its natural
host and has both biological and clinical relevance to human CMV
disease [43]. In this study, we have sought to apply a systems-level
approach, bringing together functional genomics, lipidomics, and
biochemical experimentation, to understand the interplay between
sterol pathway down-regulation and the innate immune response to
mCMV infection. Our investigations reveal a previously undis-
closed dependency role for down-regulation of the sterol metabolic
network, which is integral to the protective immune response
requiring a type 1 interferon receptor regulatory loop mechanism.
Results
Sterol Biosynthesis Pathway–Associated Genes Are Co-
ordinately Down-Regulated by IFNc Treatment and
mCMV Infection in Primary Bone-Marrow–Derived
Macrophages
As a first step, an integrative approach combining bioinfor-
matics tools and a time-series analysis of gene expression changes
was applied to mCMV-infected or interferon (IFN) c-activated
primary bone-marrow-derived macrophages (BMDM). These
primary BMDM cultures represent a physiologically relevant cell
system for the combined analysis of infection, inflammation, and
lipogenesis [44–46]. In the following experiments, infected or
IFNc-treated BMDM RNA was harvested every 30 min up to
12 h post-challenge for microarray gene expression profiling. In
this study, analysis of expression data was exclusively restricted to
lipogenic-associated genes. For this purpose, a combination of
literature and data-mining identified over one thousand genes with
published direct or indirect functions relating to cellular lipid
metabolism, regulation, and synthesis (Text S1). When this
resource was used to interrogate a subset of our time-series data
Author Summary
Currently, little is known about the crosstalk between the
body’s immune and metabolic systems that occurs after
viral infection. This work uncovers a previously unappre-
ciated physiological role for the cholesterol-metabolic
pathway in protecting against infection that involves a
molecular link with the protein interferon, which is made
by immune cells and known to ‘‘interfere’’ with viral
replication. We used a clinically relevant model based on
mouse cytomegalovirus (CMV) infection of bone-marrow-
derived cells. Upon infection these cells produce high
levels of interferon as part of the innate-immune response,
which we show in turn signals through the interferon
receptor resulting in lowering enzyme levels on the
cholesterol pathway. We observed this effect with a range
of other viruses, and in each case it leads to a notable drop
in the metabolites involved in the cholesterol pathway. We
found that the control mechanism involves regulation by
interferon of an essential transcription factor, named
SREBP-2, which coordinates the gene activity of the
cholesterol pathway. This mechanism may explain clinical
observations of reduced cholesterol levels in patients
receiving interferon treatment. Our initial investigation
into how lowered cholesterol might protect against viral
infection reveals that the protection is not due to a
requirement of the virus for cholesterol itself but instead
involves a particular side-branch of the pathway that
chemically links lipids to proteins. Drugs such as statins
and small interfering RNAs that block this part of the
pathway are also shown to protect against CMV infection
of cells in culture and in mice. This provides the first
example of targeting a host metabolic pathway in order to
protect against an acute infection.
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which passed a stringent filtering threshold (p,1026), 89% of
lipogenic-associated genes were detected, of which 12% were
significantly regulated (113/958) upon IFNc treatment and 23%
were significantly altered in their expression (195/958) after
mCMV infection. This represented a significant and highly
selective lipogenic response (Figure S1) with altered genes showing
a high degree of overlap between infection and IFNc activation
(Table S1). Notably, clear differences in the specific class of
lipogenic genes in up- and down-regulated groups were observed.
Of the IFNc down-regulated transcripts, a significant proportion
(14/35, 40%) were related to the sterol pathway, while fatty acid
pathways were pre-eminent (6/35, 17%) in the up-regulated gene
group (Figure S1C). A statistical evaluation investigating pathway
over-representation indicated a highly pathway-specific response
including previously known pathways for inositol (Table S2E–F)
[47] perturbed by mCMV infection. Significantly, however, the
most pronounced pathway changes in the down-regulated genes
common to both stimuli were associated with sterol lipid
metabolism (Table S2E and Figure 1A), which exhibited a
gradual, temporal decline in expression from 6 h post-infection
(hpi) onwards (Figure 1B). Additional microarray experiments to
further explore this observation revealed a further reduction in
sterol pathway gene expression observed at 24 hpi (unpublished
data). It is worth noting, however, that the observed level of
reduction in expression for any particular transcript was relatively
modest (ranging from 1.3- to 5-fold for infection and 1.3- to 3-fold
for IFNc treatment over a 24 h time frame).
To independently validate the microarray data described above, Q-
RT-PCR analyses of five independent experiments were performed for
both infection and IFNc treatment. In agreement, we find that Q-RT-
PCR analysis of selected members of the pathway—Hmgcs1, Hmgcr,
IdI1, and Sqle—shows a statistically significant but quantitatively
modest reduction in expression (Figure 1C and 1D). Notably, a similar
quantitative decrease is also exhibited at the protein level for
HMGCS1, HMGCR, and SQLE (Figure 2A).
Down-Regulation of the Sterol Biosynthesis Pathway Is
Specific to IFNc and IFNb Treatment
Since the alterations in expression of the cholesterol-related
genes were consistent but of relatively small magnitude, we
considered whether these perturbations represented either non-
specific ‘‘noise’’ generated during the pro-inflammatory stimula-
tion of a macrophage or a more specific response to a particular
challenge. To test whether alternative pro-inflammatory mediators
could also lead to the modulation of the sterol pathway genes,
macrophage cultures were treated with a range of doses of the
following inflammatory cytokines: IL1b, TNF, IL6, and IFNb.
Hmgcs1, Hmgcr, Idi1, and Sqle gene expression changes were then
analyzed by Q-RT-PCR (Figure 1E–H). Of the cytokines tested,
only IFNb elicited the down-regulation of sterol pathway gene
expression in primary macrophage cultures (Figure 1E). In
summary, these data indicate a highly specific response of
macrophages through a coordinated negative regulation of
multiple sterol pathway members upon viral infection or treatment
with IFNc or b but not IL1b, TNF, or IL6. Once again, these
effects are quantitatively ‘‘modest’’ but statistically significant.
Experimental Testing of Bioinformatic Predictions:
Infection Results in a Decrease of Sterol Metabolites in
Primary Macrophages and Fibroblasts
We next sought to explore how multiple small reductions in
enzyme levels impact upon the biosynthetic activity of the pathway
by measuring the steady-state metabolic output of the pathway. For
these experiments, free intra-cellular cholesterol level, as a
metabolic end product of the sterol pathway, was determined using
an enzymatic method on infected macrophages (Figure 2B). We
observe a significant decrease in cholesterol metabolite levels 24 hpi.
Similar results were also observed with infection of NIH/3T3 cells
(Figure 2C), indicating that the effect is not macrophage specific.
It is possible that the experimentally observed drop in sterol lipid
levels could be due to a non-specific and generalized response to
infection, although from the microarray analysis of the lipidomic
associated genes we clearly observe highly specific lipogenic
responses rather than a broad response to infection (Figures S1
and S2). To further determine whether the down-regulation of sterol
biosynthesis is specific between mCMV infection and select
lipogenesis pathways, total cell extracts were analyzed by electro-
spray ionization as well as atmosphere chemical ionization mass
spectrometry (see Materials and Methods). These lipidomic
approaches allow quantification of the major membrane lipid classes
(such as glycerophospholipids and sterols) as well as individual
molecular lipid species at high sensitivity. Overall, we find no
coordinated or substantial differences in the overall levels of major
glycerophospholipids (phosphatidylcholine, phosphatidylserine, and
phosphatidylethanolamine) during infection with CMV, although a
small number of the individual species in the phosphatidylcholine
and phosphatidylserine group are affected (Figure S3A–C). In
marked contrast, levels of free cholesterol, as well as its immediate
precursor, zymosterol, 14-demethyl-lanosterol, and 7-dehydrocho-
lesterol, were strongly reduced at 24 hpi (2–3-fold) and 48 hpi (4–6-
fold) (Figure S2A–D). These results further support a specific
alteration of sterol biosynthesis upon infection. Furthermore, the
reduced free cholesterol levels are also developed in a dose-
dependent manner by treatment with IFNb and c but not IL1b,
IL6, or TNF (Figure 2D). Altogether, we conclude that the effect of
the coordinated down-regulation is to reducemetabolic output of the
sterol pathway.
Pharmacologic Inhibition and siRNA Knock-Down of the
Sterol Biosynthesis Pathway Has an Antiviral Effect
To assess whether the sterol biosynthesis pathway plays a pro-
or anti-viral role in regulating mCMV replication, we exploited
the pharmacologic compound ‘‘simvastatin,’’ a potent and
selective inhibitor of HMGCR [48]. Inhibition of HMGCR is
known to result in a reduction of the metabolic intermediate
mevalonate (Figure 3) and an accompanying drop in cholesterol
synthesis by the cell [49]. The treatment of cells with simvastatin
resulted in a dose-dependent inhibition of mCMV plaque
formation (unpublished data) and in live cell replication assays
(Figure 4A) with an IC50 of 2 mM that is comparable to the ‘‘gold
standard’’ anti-viral Gancyclovir (Figure 4A) in the murine model
system. Notably, the observed inhibitory effect of simvastatin
occurred below a level at which non-specific toxic effects to cells
were observed (15 mM) (Figure S7). These experiments pointed to
a potential protective anti-viral role via a targeted disruption of the
sterol pathway and raised the question of whether pharmacologic
treatment in vivo also develops an inhibitory effect. To investigate
whether simvastatin could play an anti-infective role in vivo, mice
were administered with an established pre-clinical pharmacologic
dose of simvastatin or vehicle alone and infected by intra-
peritoneal inoculation with mCMV. Viral titres were then
determined in a variety of organs at day 4 post-inoculation.
Markedly, viral titres are reduced by over one order of magnitude
in multiple organs following treatment with simvastatin (Figure 4B).
To determine the extent of the overlap between the sterol
biosynthesis pathway and anti-viral activity, we employed a series
of metabolite rescue and interference RNA knock-down experi-
Down-Regulation of Sterol Synthesis Network by IFN
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ments. In these experiments we observed that simvastatin anti-
viral activity could be completely reversed by the addition of
mevalonate to cells in culture (Figure 5A). This showed that the
anti-viral mechanism was due to an inhibition of HMGCoA
reductase. While this result supports the requirement of the
mevalonate arm of the sterol pathway, it does not necessarily
implicate cholesterol as being responsible for the anti-viral activity.
Notably, feeding macrophages with a cell permeable form of
cholesterol or squalene failed to reverse the inhibitory activity
(Figures 3 and 5A), indicating that the anti-viral effect is unlikely to
be cholesterol mediated and thus unrelated to any regulatory
sterols or to the structural requirements of virus replication
associated with lipid droplets. The addition of cell permeable
farnesol also did not rescue the inhibitory activity of simvastatin,
while conversely the addition of geranylgeraniol fully rescued the
anti-viral activity (Figures 3 and 5A). These experiments show the
specificity of the metabolic requirement for anti-viral activity and
highlight a possible role for the mevalonate-isoprenoid arm of the
sterol pathway in protection against mCMV infection (Figure 3).
While the rescue of statin inhibition of viral growth by
mevalonate and geranylgeraniol strongly indicates the involve-
ment of the proximal arm of the sterol pathway, it is still
conceivable that other mechanisms of action unrelated to the
capacity to inhibit biosynthesis may be responsible for the effect
on virus replication. For this reason and to additionally test the
specific requirement of members of the sterol biosynthesis
pathway for viral growth control, siRNA knock-down experi-
ments were performed. For these experiments, Hmgcs1 and Hmgcr
were first targeted in the pathway using low concentrations of
siRNA to avoid non-specific interferon responses, including a
series of non-targeting siRNA for non-targeting effects. Knock-
down of these genes (Figure S5) resulted in a specific and
significant decrease in the optimal rate and end-point yield of
viral replication (Figures 5B). To further dissect the specific role
of pathway members in mediating the anti-viral response,
additional siRNA inhibition studies were conducted involving
targeted genes distal to the mevalonate-prenylation branch of the
sterol biosynthesis pathway. In these experiments, Fdft1, Sqle,
and Dhcr7 were targeted. Figure 5B clearly shows that targeting
these members of the pathway fails to inhibit and even positively
influences viral growth, a result that is consistent with the above
described metabolite rescue experiments. To further investigate
and to independently assess the specificity of the prenylation
branch of the pathway, additional siRNA knock-down experi-
ments were performed targeting farnesyl diphosphate synthase
(Fdps), an enzyme essential for isoprenoid biosynthesis, and all
three prenyltransferases (these are farnesyltransferase, geranyl-
geranyltransferase type I, and Rab geranylgeranyltransferase
type II enzymes). In these experiments knock-down of Hmgcr
and Dhcr7 and viral ORFs (M54 and M86) are used as controls
and developed the expected knock-down profile (Figure 5C).
Notably, significant inhibition of viral replication is observed for
knock-down of Fdps. In the case of the downstream prenyl-
transferases, reduced viral replication is observed with siRNA
targeting Rabggtb specific for geranylgeranyltransferase type II
enzyme, but not Pggt1b or Fntb specific for gernylgeranyltrans-
ferase type I and farsenyltransferase, respectively (Figure 5C).
These experiments indicate specificity of targeting the isoprenoid
pathway but will require further functional validation work.
Overall, these findings show that inhibition of viral growth is not
due to cholesterol deprivation, but rather a part of the pathway
involving a proximal mevalonate-prenylation step. This raises the
notion of whether depletion of geranylgeraniol may be one potential
mode for interferon to inhibit viral replication. In this scenario we
might expect that feeding cells with geranylgeraniol upon interferon
treatment would counter, in part, the anti-viral effect. To determine
the effect of interferon on viral replication, in the absence and
presence of geranylgeraniol, we performed a metabolite rescue
experiment in the presence of increasing units of IFNb. Figure 5D
shows that the anti-viral effect of 1 and 5 U/ml of IFNb is
dramatically reduced in the presence of geranylgeraniol (at both 15
and 150 mM), while at a more potent level of IFNb (at 25 U/ml)
approximately 70% and 25% of the anti-viral activity remains with
15 and150 mM GGOH, respectively. Taken together, these results
support a role of the mevalonate-isoprenoid arm of the sterol
pathway for optimal mCMV replication and highlight the potential
role for down-regulating this pathway in protecting the host from
viral infection. These findings also suggest that sterol biosynthesis
regulation acts as a marker for antiviral activity.
An Interferon Regulatory Loop Is Responsible for the
Transcriptional Down-Regulation of the Sterol
Biosynthesis Pathway in Response to Infection
We next sought to investigate whether specific viral or cellular
modes of action might be responsible for the reduction in sterol
biosynthesis upon infection. First, it is possible that the effects
monitored in our experimental system are specific to mCMV. To
test whether the down-regulation of sterol pathway gene
expression is a more general effect rather than specific to mCMV,
primary macrophages (BMDM) were infected with a number of
different viruses and harvested for gene expression analysis.
Figure 6A shows the expression profile of the sterol pathway and
other pathways for infection (innate immune activation pathways)
by an enveloped DNA virus, herpes simplex (HSV1); an RNA
virus, semliki forest virus (SFV); cytoplasmic DNA virus, vaccinia
virus (VV); and non-enveloped nuclear DNA virus, adenovirus. All
the viruses tested show a specific and coordinate decrease in gene
expression for members of the sterol biosynthesis pathway.
In the case of mCMV, it is worth noting that the reduction in
gene expression occurs approximately 6 hpi (e.g., see Figure 1).
Consequently, it is possible that a viral early or late gene product
may be required for the effect. To test this possibility, we used a
replication and early/late gene defective mCMV virus
(mCMVdie3 in [50]). The mCMVdie3 strain is capable of
infecting cells at levels equivalent to wild-type virus but is
incapable of expressing its genome downstream of a rather
Figure 1. Regulation of the cholesterol pathway upon mCMV infection. (A) The Sterol biosynthesis pathway shown in KEGG notation with
abbreviated metabolites (abbreviations listed in Text S1). The geranylgeranylation pathway responsible for GGPP synthesis is shown in the dashed
box. (B) Heat map of the cholesterol biosynthesis temporal genes’ expression during the first 12 h of mCMV infection (left panel) or IFNc treatment
(right panel). Each time point corresponds to one independent biological sample, and columns indicate time in hours. Fold changes of expression
levels are represented on a Log2 scale compared to mock-treated cells, ranging from a 0.86 lower expression (dark blue) to a 1.26higher expression
(bright yellow). (C–H) Expression analysis measured by qRT-PCR of Hmgcs1, Hmgcr, Idi1, and Sqle genes in BMDM infected with mCMV(24 hpi) (C) or
treated for 24 h with IFNc (10 and 100 U/ml) (D), IFNb (10 and 25 U/ml) (E), IL6 (10 and 25 U/ml) (F), IL1b (10 and 100 U/ml) (G), or TNF (10 and 100 U/
ml) (H). Graphs show levels of mRNA expression of the respective genes either infected or cytokines-treated relative to mock samples. Bars represent
the means 6 SD of five independent experiments with biological triplicates for each experiment. *p,0.05, **p,0.01, ***p,0.001, determined with
an unpaired Student’s t test.
doi:10.1371/journal.pbio.1000598.g001
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Figure 2. Effect of a coordinated reduction in multiple enzymes on sterol biosynthesis. (A) Comparison by Western blot analysis of
HMGCS1, HMGCR, and SQLE protein levels in mCMV infected (24 hpi) or mock-treated BMDM. Infection was measured by detection of the IE1 mCMV
antigen. Intensity values relative to b-actin calculated by densitometry show a decrease of the total amount of protein in the mCMV-infected BMDM
compared to the mock-treated samples of 64% for HMGCS1, 50% for HMGCR, and 85% for SQLE. Graphs are representative of two independent
experiments with biological duplicates and triplicates, respectively. (B–C) Free cholesterol concentration was determined experimentally by
enzymatic assay (Materials and Methods) at 0, 6, 24, 48, and 72 hpi in BMDM (B) and NIH/3T3 cells (C). Cholesterol content is presented as the
percentage of free intracellular cholesterol concentration from infected cells compared to mock treatment. Graphs represent the means 6 SD of
three independent experiments with biological quadruplicates for each experiment. (D) Free cholesterol concentration in BMDM cultures treated
with varying concentrations of IFNc, IFNb, TNF, IL1b, or IL6. The cholesterol concentration was measured as mentioned above after 48 h post-
cytokine treatment. Bars represent means 6 SD of two independent experiments with biological quadruplicates for each experiment. *p,0.05,
**p,0.01, ***p,0.001, determined with an unpaired Student’s t test.
doi:10.1371/journal.pbio.1000598.g002
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restricted immediate-early phase. The results of these experiments
are shown in Figure 6B, in which mCMVdie3 potently develops
an equivalent level of down-regulation of sterol genes as the
parental wild-type and revertant viruses, respectively.
It is well established for many viruses, including mCMV, that
infection leads to the induced expression of type 1 interferon and
pro-inflammatory cytokines. Two signaling cascades—a virus-
induced interferon-producing signal and an interferon receptor-
mediated secondary signal—regulate the interferon system. The first
is initiated by the detection of viral components by host recognition
receptors (PRRs) and leads to the activation of transcription
factors—NFkB, ATF2/c-Jun, IRF3, and IRF7—that activate IFNa
and b genes. The expressed interferons then transmit a secondary
autocrine or paracrine signal through interactions with type I
receptors that activate the JAK-STAT pathway. In this context, the
above studies with the combined observation that interferon
treatment and the cell response to infection are equally capable of
causing a down-regulation of the sterol metabolic pathway raise the
question of whether infection-mediated regulation might result from
an interferon regulated loop. In support of this notion we find that
Figure 3. Schematic of the mevalonate-isoprenylation branch point of the sterol biosynthesis pathway. Metabolites (shown in inverse
print) and inhibitor (Simvastatin) (shown in grey) used to dissect the pathway are indicated: Simvastatin inhibits HMGCR and prevents the synthesis of
mevalonate and downstream lipids.
doi:10.1371/journal.pbio.1000598.g003
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low multiplicities of infection still exhibit a significantly reduced level
of free cholesterol (Figure S6) and that conditioned media from
infected macrophages 8 hpi (prior to release of any new viral
particles) are sufficient to down-regulate the sterol biosynthesis
pathway genes in uninfected control cultures (Figure 6C).
On the basis of temporal expression, causal inference of
candidate effectors can be tested. A search of cytokine profiles
suggested a strong correlation following IFNb synthesis, further
raising the hypothesis for a potential interferon regulatory loop
mechanism that is responsible for modulating sterol biosynthesis.
First, we investigated directly whether IFNb is responsible by
infecting BMDM from ifnb2/2 mice and examining gene
expression for representative members of the sterol pathway.
Figure 7A shows that following the genetic ablation of IFNb, there is
still statistically significant sterol gene expression reduction but that
there is a partial loss in the degree of reduction indicating that IFNb
is not absolutely necessary. It is possible that other type I IFN
members may compensate for the lack of IFNb. The redundancy
among the various type I interferons can be directly evaluated
through genetic knockout of their shared receptor, IFNAR1.
For this reason we next investigated whether the sterol response
to infection is dependent on the type I interferon receptor. To this
end, primary macrophages derived from IFNAR12/2 mice were
challenged with mCMV or IFNb, and the sterol biosynthesis gene
expression and free cholesterol levels were analyzed. As shown in
Figure 7B–D, the lack of interferon type I receptor abolished the
ability of macrophages to reduce both sterol biosynthesis gene
expression and cholesterol yield upon either infection with mCMV
or treatment with IFNb. We conclude from these experiments that
a type I interferon-dependent innate immune response stringently
regulates the metabolic alteration of the sterol biosynthesis
network observed upon infection.
Type 1 interferon has an important role in the control of
mCMV replication, and the tyrosine kinase 2 (Tyk 2) signaling
component is absolutely essential for the type I defense against
mCMV infection. Notably, the lack of Tyk2 is known to selectively
impair the transcription of only a subset of virally induced
IFNAR1 responsive genes [51]. Since this occurs at the promoter-
transcriptional level, we first asked whether the down-regulation of
the sterol pathway in response to infection also occurs at the level
of gene transcription. For this purpose and to directly measure the
level of de novo transcription of members of the sterol pathway, we
exploited a recently established labeling protocol for the isolation
and analysis of newly transcribed RNA [52]. In these experiments,
macrophages were infected with mCMV in the presence of 4-
thiouridine, for 30 min at 6 hpi, allowing efficient labeling of
nascent RNA for isolation and interrogation by microarray
analysis. Figure 8A shows that infection by mCMV results in the
anticipated reduced level of newly transcribed RNA of the sterol
biosynthetic pathway genes. Next we sought to test whether the
Tyk2 receptor-signaling component is required for the type I
interferon-dependent down-regulation of the sterol pathway. For
these experiments we used tyk22/2 macrophages and observe an
almost complete abrogation of the transcriptional down-regulation
by mCMV infection (Figure 8B). These results demonstrate a
requirement for Tyk2 in the mCMV-mediated gene down-
regulation of the sterol biosynthesis pathway and suggest a novel
role of interferon type I receptor signaling as a transcriptional
modifier of the host’s metabolic response to infection.
SREBP2 Is Down-Regulated upon Infection and IFN
Treatment by a Type I Interferon-Dependent Mechanism
The above studies strongly point to a transcriptional mechanism
in down-regulating the sterol pathway upon infection. The sterol
regulatory binding protein 2 (SREBP2) is the principal transcription
factor involved in coordinating the regulation of the sterol
biosynthesis pathway [53]. SREBP2 is synthesized as a precursor
and anchored in the endoplasmic reticulummembrane and through
limited proteolysis is activated to generate mature forms that can
enter the nucleus and interact with multiple sterol pathway genes to
coordinate their expression. Hence, in order to gain further insight
into the potential mechanism for participating in the transcriptional
down-regulation of the sterol pathway, we investigated in the first
instance the protein levels of activated cleaved forms of SREBP2
Figure 4. Effect of statins on mCMV growth in vitro and in vivo.
(A) NIH/3T3 cells were infected with mCMV-GFP (MOI of 0.2) and
subsequently treated with varying concentrations of Simvastatin or
Gancyclovir immediately after infection. GFP expression was measured
to monitor the level of infection (Materials and Methods). Graph
represents the percentage of viral inhibition as a function of drug
treatment. Data points represent mean 6 SD of two independent
experiments with six biological replicates for each experiment. (B) Mice
were fed with simvastatin (50 mg/kg/mice) daily for 5 d by gavages and
at day 1 post-treatment, were challenged with 26106 PFU of mCMV by
intraperitoneal injection, and sacrificed; at 4 dpi, viral titers in different
organs were measured by plaque assay and are expressed per gram of
tissue. Data points represent mean 6 SD of two independent
experiments with five mice per group for each experiment. *p,0.05,
**p,0.01, ***p,0.001, determined with a Mann-Whitney U test.
doi:10.1371/journal.pbio.1000598.g004
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Figure 5. Metabolic investigation of the sterol pathway in infection. (A) NIH/3T3 cells were infected with mCMV-GFP (MOI of 0.2) and
subsequently treated with Simvastatin (SMV) (2.5 mM) and mevalonate (MEV) (300 mM) or geranylgeraniol (GGOH) (15 mM) or farnesol (FOH) (15 mM)
or squalene (SQE) (15 mM) or of water soluble cholesterol (complexes of cholesterol with methyl-b-cyclodextrin, CHO/MCD) (5 mg/ml) for 72 h. The
level of infection was determined by measuring GFP fluorescence at 76 hpi (Material and Methods). Graph represents the relative level of infection
compared to the untreated cells, and bars represent mean values 6 SD of three independent experiments with five biological replicates for each
experiment. (B) NIH/3T3 cells were transfected for 48 h with either non-targeted, eGFP, Hmgcs1, Hmgcr, Sqle, Fdft1, or Dhcr7 On-target plus siRNA
smart pool and then infected with mCMV-GFP (MOI of 0.2). (C) NIH/3T3 cells were transfected for 48 h with either Risc Free, M54, and M86 (knocking
down mCMV viral genes), Hmgcr, Dhcr7, Fdps, Fntb, Pggt1b, or Rabggtb On-target plus siRNA smart pool, and then infected with mCMV-GFP (MOI of
0.2). The level of non-targeted siRNA (B) and Risc Free (C) treated cells was used as a baseline estimate for the cutoff point (two standard deviations
and a p value,0.001 (determined with an unpaired Student’s t test) as significant). Bars represent means6 SD of two independent experiments with
three biological replicates for each experiment. (D) NIH/3T3 cells were incubated with various doses of IFNb for 18 h in the presence or absence of 15
and 150 mM GGOH. The graph represents the inhibition of viral replication (in percentages) as a function of drug concentration. Bars represent mean
6 SD of biological triplicates for each experiment. *p,0.05, **p,0.01, ***p,0.001, determined with an unpaired Student’s t test.
doi:10.1371/journal.pbio.1000598.g005
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upon infection and interferon treatment. Accordingly, we next
performed Western blot experiments to determine levels of mature
form of SREBP2. In these experiments, infection of macrophages
with mCMV at 24 hpi developed a significant decrease in the
nuclear form (Figure 9A). Furthermore, treatment of macrophages
with either IFNb or IFNc clearly exhibits a decrease in SREBP2
levels (Figure 9A). We next sought to examine whether this is also
seen at the level of transcription. In experiments measuring de novo
RNA synthesis, we observed a specific transcriptional reduction
from the Srebf2 gene upon infection while increased levels of
transcription are seen for interferon-associated transcription factor
Stat1 (Figure 9B), indicating a selective transcriptional basis for the
reduced levels of expression. Markedly, the reduction in RNA levels
upon infection was completely reversed upon genetic ablation of the
ifnar1 gene (Figure 9C). Altogether these results demonstrate a
coordinate reduction in SREBP2 at both the protein and RNA
expression level upon infection, which is tightly dependent on
activation of the type 1 interferon receptor.
Discussion
Through the application of a pathway biology strategy
integrating genomic, lipidomic, and biochemical approaches with
bioinformatics, we show, for the first time, the coupling of the type
I interferon response upon viral infection to the sterol pathway and
identify the mevalonate-isoprenoid arm as playing a pivotal role in
antiviral functions. A definitive link to sterol metabolism that is
independent of cholesterol is established by the observation that
the anti-viral effect of down-regulating the sterol pathway upon
infection is completely blocked if cells are provided with an excess
of mevalonate but not cholesterol. Furthermore, the anti-viral
potency of type 1 interferon is severely diminished in the presence
of excess geranylgeraniol metabolite, highlighting a requirement of
the mevalonate-isoprenoid branch as part of an interferon
mechanism for protecting against infection. Further on the basis
of genetic elimination studies we unequivocally document a
molecular dependency between sterol biosynthesis and interferon
signaling upon infection, leading to a modest but highly significant
coordinate decrease in gene expression, which subsequently causes
a marked alteration in the metabolic activity of the sterol pathway.
A Two-Step Immune-Signaling Cascade Involved in
Regulating Sterol Biosynthesis upon Infection
Our results are consistent with a model involving a two-step
interferon response for modulating endogenous sterol pathway
activity upon infection. Figure 10 illustrates the two signaling
cascades, a virus-induced interferon-producing signal and an
interferon receptor-mediated secondary signal. The first is initiated
by the detection of virion proteins and nucleic acids by host
recognition receptors with the result of the infected cell producing
type I interferon. As part of the second step all type I interferons
bind to one common receptor (IFNAR1). The IFN-a/b receptor
(IFNAR1) signals through the JAK/STAT pathway by phosphor-
ylation of the Janus kinase (JAK)1, tyrosine kinase (Tyk)2, and signal
transducer and activator of transcription (STAT)1 and STAT2,
which subsequently modulates a diverse array of genes. In the case
of mCMV the first step has been extensively investigated and shown
to involve TLR2, TLR3, and TLR9 recognition receptors [54,55],
whose activation leads to the induction of transcription factors,
NFkB, ATF2/c-Jun, and IRF3 that directly activate IFNa and b
genes. Interestingly, previous studies [5,37] have shown that
microbial activation of TLR3 or TLR4 inhibits by an as-yet
unknown mechanism LXR target genes such as ABCA1, resulting
in the inhibition of cholesterol efflux from macrophages. This is
reported to occur in a type I interferon-independent manner [5].
Similar to microbial-mediated TLR activation of IRF3, many
viruses including mCMV potently induce IRF3 and may also have
the potential to inhibit LXR functions. Despite recent progress in
the definition of links between intracellular cholesterol homeostasis
and innate immunity, little is known regarding the influence of
interferon-regulated signaling on this phenomenon.
In the present study, we demonstrate that transcriptional
regulation of the cellular sterol biosynthesis pathway upon
infection has an impact on viral replication and depends on an
interferon-regulated loop involving type 1 interferon signaling.
Specifically, we show that infection of cells by a wide range of
viruses or direct interferon stimulation is accompanied by the
down-regulation of sterol biosynthesis as a result of reducing the
rate of sterol gene transcription. In the context of ligand-activation
of the type I receptor, we also demonstrate that this requires the
Tyk2 signaling component (Figure 10).
In the context of type I interferon genes induced upon infection, it
is worth noting that viperin, a type I interferon-regulated gene, is
involved in cellular defense against a number of viruses and functions
to disrupt cholesterol-rich lipid rafts that are used as viral production
sites in the cell [34,38,56]. In addition, an intracellular interaction of
viperin with Fdps, an enzyme essential for isoprenoid biosynthesis
(Figure 3), has been reported to lower, by a small extent, the activity of
the enzyme [38]. It is not known whether targeting Fdps enzyme
activity alone is an effective anti-viral mechanism, although the RNAi
targeting results of Figure 5 (panel C) suggest that this may be a
plausible mechanism (Figure 5C). However, it is more likely that a
combination of interferon-mediated transcriptional down-regulation
of the sterol biosynthesis genes and the potential enzymatic protein
modification at the isoprenoid branch point represents a concerted
anti-viral host defense mechanism.
Coordinate Transcriptional Regulation of Sterol Pathway
Members
From a transcriptional perspective, the sterol biosynthesis
pathway genes are co-ordinately controlled by the sterol regulatory
Figure 6. Alteration of gene expression upon HSV1, SFV, VV, adenovirus, and non-infectious mCMV in primary macrophages. (A)
Heat map of expression levels of a set of genes after 24 h mock treatment, infection with Herpes simplex virus 1 (HSV1), Semliki forest virus (SFV),
Vaccinia virus (VV), or Adenovirus (Ad) in BMDM (Text S1). Genes represent the innate immunity activation, the MHC class II antigen presentation, and
the cholesterol and unsaturated fatty acids biosynthesis. Each square represents a single biological replicate. Fold changes of expression levels are
represented on a Log2 scale compared to mock-treated cells, ranging from a 0.46 lower expression (dark blue) to a 1.66higher expression (bright
yellow). (B) Expression analysis measured by qRT-PCR of Hmgcs1, Hmgcr, Idi1, and Sqle genes in BMDM after 24 h mock treatment, mCMV, or
mCMVdie3 infection, respectively. Graphs show the level of expression of the indicated genes relative to mock-treated samples and bars represent
mean 6 SD of two independent experiments with triplicate biological measurements for each experiment. (C) BMDM were infected with mCMV or
mock treated, and supernatant was collected after 8 h and directly added to fresh BMDM. After 24 h, RNA from these cultures was collected and
Hmgcs1, Hmgcr, and Sqle expression were measured by qRT-PCR. To test for the presence of any detectable virus, an aliquot of the supernatant was
used to perform a standard plaque assay (no infectious virus detected, unpublished data). Graphs show the level of expression of the indicated genes
relative to mock-treated samples and bars represent means6 SD of three independent experiments with triplicate biological measurements for each
experiment. *p,0.05, **p,0.01, ***p,0.001, determined with an unpaired Student’s t test.
doi:10.1371/journal.pbio.1000598.g006
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element binding protein 2 transcription factor (SREBP2).
Significantly, we find in our system that the overall abundance
of the mature protein (the proteolytically cleaved active form) and
the rate of gene transcription of its gene are significantly reduced
upon infection or interferon treatment. Significantly, both are
strictly dependent on the presence and activation of the type 1
interferon receptor Ifnar1. These findings suggest that a possible
mechanism for the coordinate down-regulation of sterol biosyn-
thesis is by interferon regulation of Srebf2. Interestingly and
consistent with the possibility of interferon regulating Srebf2,
chemical inhibition of SREBP2 has been shown to inhibit HCV
replicon activity [32]. This would also support the view of
Figure 7. Contribution of type I interferon response in the regulation of sterol biosynthesis genes upon infection. (A–C) Wild type
BMDM or BMDM from IFNb2/2 knockout mice or from IFNAR12/2 knockout mice were mock treated, infected with mCMV, or treated with IFNb
(10 U/ml) for 24 h. RNA was collected and the gene expression of Hmgcs1, Hmgcr, Idi1, and Sqle was measured by qRT-PCR. Graphs show the level of
expression of the indicated genes relative to mock-treated samples. Bars represent the mean 6 SD of biological quadruplicates. (D) Wild type BMDM
or BMDM from IFNAR12/2 knockout mice were infected with mCMV or treated with IFNb (10 U/ml). After 48 h, free cholesterol concentration was
measured by enzymatic assay (Materials and Methods). Bars represent the mean 6 SD of biological quadruplicates. *p,0.05, **p,0.01, ***p,0.001,
determined with an unpaired Student’s t test.
doi:10.1371/journal.pbio.1000598.g007
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implicating negative feedback on SREBP-2 via oxysterol metab-
olites. Further studies are required to elucidate more precisely the
mechanism or mechanisms by which interferon mediates down-
regulation of the sterol biosynthesis pathway. Whatever the
mechanism, the IFN-dependent coupling of the mevalonate-sterol
metabolic network and anti-viral activity represents a previously
unrecognized mechanism in the regulation of protective immunity.
From an immune response and metabolic/pharmacological
perspective, modulating cholesterol biosynthesis via small, coordi-
nate transcriptional changes offers advantages and disadvantages
over single enzyme control. At the homeostatic level, coordinate
control of a metabolic pathway could potentially increase the
robustness of modulation; the redundant rate-limiting interactions,
downstream of the true rate-limiting interaction, can protect the
pathway from surges in the levels of downstream metabolites.
Coordinate control also increases the specificity of the pathway
modulation as a small reduction of the enzyme level in an
interaction ensures that the level of the interacting metabolite need
not drop as far to affect a reduction in flux. This has the advantage
of potentially lessening the impact on other branched or cross-
linked pathways that use the same metabolites and thus provides a
high degree of pathway specificity.
Figure 8. Measurement of de novo mRNA synthesis of sterol biosynthesis genes upon viral infection.Wild Type or Tyk22/2 BMDM were
infected with mCMV at an MOI of 1 for 1 h. De novo RNA was labeled between 360 and 390 min post-infection, isolated, and hybridized to Affymetrix
Gene 1.0 ST microarrays (Materials and Methods). After scanning and data capture, gene expression in mock-infected or infected cells was analyzed,
and for the purposes of presentation, gene expression values from control (mock infected) BMDM (black) were adjusted to a value of 1. Values for
expression in infected cells (white) were then expressed as a number relative to the control.
doi:10.1371/journal.pbio.1000598.g008
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Therapeutic Perspective
Several viruses including human CMV have been reported to
be sensitive to statin administration [25,26,28–31]. Although the
mechanism of action of most is not known, it has in some cases
been correlated with a lower abundance of cholesterol in lipid rafts
of cell membranes. A recognized potential complicating factor of
using statins to specifically reduce cholesterol levels is that
suppression of the proximal mevalonate arm also perturbs the
synthesis of branch derivatives such as geranylgeraniol and
farnesol involved in the protein farnesylation and prenylation
pathways. In the case of HCV, the mechanisms of the inhibitory
effects of the statins have been examined extensively and have
been shown to relate to the prenylation of a host protein (FLB2)
essential for viral replication [18,57]. Recently a combination
chemical screening study has been conducted to explore how the
sterol and protein prenylation pathways work together to affect
HCV in a replicon assay [32]. In agreement with those studies we
also find reduced mCMV growth in siRNA knock-down
experiments targeting enzymes in the isoprenod biosynthesis
pathway. These studies indicate the importance of the geranylger-
anylation to viral replication. Although, it is worth noting that the
isoprenoid biosynthesis pathway is highly complicated with
multiple branch points involving redundant enzymatic steps,
sharing of subunits, and competing reactions. In our current study,
we uncoupled the cholesterol synthesis pathway from non-steroidal
modifications through targeted metabolic rescue and siRNA
knock-down studies of mCMV and reveal an absolute requirement
for the prenylation branch of the sterol pathway for mediating
anti-viral effects. As further indicated from computational
modeling work (unpublished data), targeting HMGCR is likely
to have a broad range of non-specific effects on various efferent
branch points of the pathway and thus may well not be ideal for
anti-infective therapy. In addition, statins are also known to have a
range of immune-modulatory activities by mechanisms yet to be
fully characterized. In this context, it is worth noting that the
activity of the type I interferons, especially IFNb, have
considerable overlap with many of the immune-related activities
of statins [58]. Moreover, it is especially noteworthy that IFNb
treatment in patients has also been reported to have decreased
plasma cholesterol levels [59,60]. Since our studies uncover a
Figure 9. Regulation of SREBP2 by mCMV infection and IFNb treatment. (A) Comparison of cleaved SREBP2 protein in mock-infected (lane
1), mCMV-infected (MOI of 1) (lane 2), mock-treated (lane 3), IFNb- (50 U/ml) (lane 4), or IFNc- (50 U/ml) treated (lane 5) BMDM for 24 h by Western
blot analysis using YY1 as a loading control. Arrow indicates SREBP2 cleaved form that is induced upon lovastatin and ezetimibe treatment from liver
extracts of cholesterol-fed mice (see Figure S8). The blot is representative of two independent experiments with biological triplicates for each
experiment. (B) Wild type BMDM were infected with mCMV for 1 h. De novo RNA was labeled between 360 and 390 min post-infection, isolated, and
hybridized to Affymetrix Gene 1.0 ST microarrays (Materials and Methods). After scanning and data capture, gene expression in mock-infected or
infected cells was analyzed, and for the purposes of presentation, Srebf2 gene expression values from control (mock-infected) BMDM (black) were
adjusted to a value of 1. Values for expression in infected cells (white) were then expressed as a number relative to the control. (C) BMDM from wild
type or IFNAR12/2 knockout mice were treated with 10 U/ml of IFNb or infected with mCMV. After 24 h, RNA was collected and the gene expression
of Srebf2 was measured by qRT-PCR. Results show the level of gene expression of the treated or infected samples relative to the mock-treated
samples. Bars represent the mean 6 SD of biological quadruplicates. *p,0.05, **p,0.01, ***p,0.001, determined with an unpaired Student’s t test.
doi:10.1371/journal.pbio.1000598.g009
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molecular dependency of type 1 signaling, including a Tyk2
signaling component, this may provide an entirely new therapeutic
pathway for lowering cholesterol. Moreover, our findings may
have important implications for the development of broadly active
new adjuvant strategies (e.g., the use of inhibitors of SREBP2
activity) to existing anti-infective therapies (e.g., antiviral drugs
such as ganciclovir). On this basis we posit the principal of using
metabolic modifiers, i.e. drugs that target metabolic pathways, of
protective innate immunity as holding future promise for
developing host-directed anti-viral therapies. Overall, this study
supports the original concept [40,41] of selectively targeting host
pathways as an efficacious anti-infective strategy.
Materials and Methods
Microarray Experiment, Bioinformatic Analysis
Microarray analysis of the time course experiments of infected
and interferon treated macrophages were conducted using Agilent
microarray platform and a detailed description of the experimental
set up; statistical and bioinformatics analysis is in the Supporting
Information section. All other microarray studies were conducted
using Affymetrix (Mouse Genome 430) microarray platform. Data
from hybridized Affymetrix microarrays were acquired using
proprietary Affymetrix platform scanners and GCOS software
(Affymetrix). Processed CEL files were imported into Partek
Genomics SuiteTM (MO, USA), then background corrected,
quantile normalized, and probe-set summarized using the RMA
algorithm [61,62]. A non-specific filter was applied to remove
genes that were not expressed on any of the samples across the
experiment. Microarray signals were then per-gene normalized to
the average of the three mock samples (which was set to a value of
1) for visualization purposes in the heat map for Figure 6. In the
case of de novo RNA expression, analysis was performed using the
Affymetrix Mouse Gene 1.0 ST arrays, consisting of a total of eight
chips and three experiment factors: time (60–90 min, 360–
390 min), genetic background (Tyk2KO, WT), and treatment
(mock, mCMV). Data from hybridized chips were acquired using
GCOS software (Affymetrix). Prior to further processing and
analysis with the R statistical programming environment,
Affymetrix Power Tools (APT, Affymetrix) were used to
summaries and annotate chip data to gene level. After initial
quality control assessment, data were background-corrected,
quantile normalized, and probe-set summarized using the RMA
algorithm.
Mice BMDM Cultures
Wild type C57BL/6 and BALBc were from the Biomedical
Research Resources, Little France, University of Edinburgh.
IFNb2/2 and Tyk22/2 mice were from the Institute of Animal
Breeding and Genetics Veterinary University of Vienna. BMDM
were derived from monocytes obtained from femurs of male mice
aged 10 to 12 wk. Cells were grown in DMEM-F12 media
supplemented with 10% L929 cell-conditioned medium as a
source of macrophage colony-stimulating factor (M-CSF) for 7 d
as described [63]. Characterization of BMDM was performed by
standard flow cytometry, evaluating the presence of the F4/80
marker and CD11b surface protein. In average of all experiments
more than 93% of cells possessed both proteins.
Viruses
The mouse CMV C3X strain, generated from the recombinant
C3X bacterial artificial chromosome clone and originally derived
for the Smith strain of mCMV [64], was propagated in NIH 3T3
cells, and titers were determined by standard plaque assay on
MEFp532/2. For live cell assay, NIH/3T3s were infected with a
recombinant mCMV expressing the green fluorescent protein
(GFP) marker inserted in front of the ie2 gene (pSM3fr-rev, called
mCMV-GFP in this study [65]). Viral growth curves comparing
wild type and GFP virus were assessed by standard plaque assay,
and the results showed no differences between the growth curve of
the two viruses (unpublished data). To establish the role of viral
gene expression in the regulation of sterol genes, the mCMVdie3
strain was used [50]. For the microarray experiment, Semliki
Forest Virus (SFV, MOI of 10), Herpes simplex virus type 1
(HSV1, MOI of 1), Vaccinia virus (VV, MOI of 1), and
Adenovirus (Ad, MOI of 100) were used to infect BMDM for
1 h in DMEM:F12 3% FCS, 10% L929, and 100 U of penicillin/
streptomycin per ml.
Infection
BMDM and NIH/3T3 were infected with the different viruses
at an MOI of 1, unless specified. For BMDM, viral stock was
diluted in DMEM:F12 3% FCS, 10% L929, and 100 U of
penicillin/streptomycin per ml, and after 1 h adsorption, cells
were washed in PBS and incubated in fresh DMEM:F12 10%
Figure 10. Proposed model for down-regulation of the sterol
synthesis by type I interferon response to viral infection.
doi:10.1371/journal.pbio.1000598.g010
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FCS, 10% L929, and 100 U of penicillin/streptomycin per ml.
For NIH/3T3 viral stock was diluted in DMEM 3% CS and
100 U of penicillin/streptomycin per ml, and after 1 h adsorption,
cells were washed in PBS and incubated in fresh DMEM:F12 10%
CS and 100 U of penicillin/streptomycin per ml. SFV (MOI of
10), HSV1 (MOI = 1), VV (MOI of 1), and Ad (MOI of 100) were
used to infect BMDM for 1 h in DMEM:F12 3% FCS, 10% L929,
and 100 U of penicillin/streptomycin per ml.
Cytokines and Pharmacological Treatments
IFNc (Boehringer Manheim Corp), IFNb, IL6, TNF, and IL1b
(Biosource International, USA) stock were dissolved in PBS
supplemented with 0.2% BSA and diluted in fresh media just
prior to the experiment. The effect of cytokine treatment on cell
viability was tested for each concentration used in the experiment
and did not show any alteration of viability. For the pharmaco-
logical experiment, 25 mg of simvastatin (Sigma-Aldrich) was
activated by hydrolysis of the lactone by adding 1 ml of 0.1 N
NaOH, 100% ethanol. After heating at 50uC for 2 h, the solution
was neutralized with HCl to a pH of <7.2 and sterilized by
filtration through a 0.2 mm filter. The stock solution was diluted to
the appropriate concentration in sterile PBS and the solution was
aliquoted, stored at 220uC, and used within a month of
activation. Mevalonate and water soluble cholesterol (Sigma-
Aldrich, Germany) was resuspended in media to the appropriate
concentration and sterilized by filtration through a 0.2 mm filter.
Geranylgeraniol and farnesol squalene (Sigma-Aldrich, Germany)
stocks were dissolved in DMSO and sterilized by filtration through
a 0.2 mm filter. The stock solutions were dissolved in media at the
appropriate concentration just prior to the experiment. The final
concentration of DMSO in media did not exceed 0.1%. Effects of
sterol intermediates treatment on the cell were tested for each
concentration used in the experiment and did not show any
alteration of viability. Gancyclovir (Cymevene, Hoffman-La
Roche, UK) was resuspended in saline solution and sterilized by
filtration through a 0.2 mm filter. Gancyclovir was then diluted in
media, to the indicated concentration.
Quantitative RT-PCR
Taqman Primer probe sets were purchased from Applied
Biosystems, Warrington, UK (Assay ID: Hmgcs1: Mm00524111-
m1; Hmgcr: Mm01282499-m1; Idi1: Mm00836417-g1; Sqle:
Mm00436772-A1). For each sample QRT-PCR was performed in
20 ml volumes using MicroAmp Optical 96-well reaction plates
and MicroAmp Optical Caps (Applied Biosystems). Two micro-
liters of diluted RNA samples (<100 ng of RNA) were added to
10 ml of 26PCR master mix, 1 ml of a Taqman primer/probe set
(Applied Biosystems, CA) for the gene of interest at the
recommended concentration, 0.25 ml of Superscript III (Applied
Biosystems, CA), and 6.25 ml of double-distilled H20. After an
initial incubation at 50uC for 30 s to activate the RNA
polymerase, samples were then subject to 40 cycles under Taqman
standard conditions (combined annealing and primer extension
phase at 60uC for 1 min and a short denaturation at 72uC for
30 s). Stratagene MXPro software was then used to analyze the
data. Threshold determinations were automatically performed by
the instrument for each reaction. The CT values were exported
into Microsoft Excel and relative quantification of marker gene
mRNA expression was calculated with the comparative CT
method [66].
Western Blot Analysis
BMDM cells were washed with PBS and resuspended in whole-
cell lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1%
NP40, protease inhibitors, and phosphatase inhibitors), and cell
lysates were centrifuged at 4uC for 10 min and the collected
supernatants were stored at 220uC. Protein concentration was
measured by Pierce BCA assay (Thermo Scientific). For Western
blotting, proteins were separated by SDS-PAGE, transferred to
Immobilon-FL membranes (Millipore), and probed with goat anti-
HMGCR (Santa Cruz, sc-27578, 1:500), goat anti-SQLE (Santa
Cruz, sc-49754, 1:500), anti-HMGCS1 (Santa Cruz, Sc-32422,
1:500), mouse anti-mCMV IE1 (Chroma 101, 1:1000), and rabbit
anti-b-actin (Cell Signalling, 4970, 1:2500) diluted in PBST (0.1%
Tween20). For secondary anti-goat IR-680 (Invitrogen, A21088,
1:10,000), IR-800 anti-mouse (Thermo Fisher Scientific, 35571,
1:10,000), and IR-800 anti-rabbit (Cell Signalling, 5151, 1:10,000),
antibodies were diluted in Odyssey blocking buffer (0.1%
Tween20, 0.01% SDS). For probing, visualization, and quantifi-
cation, the Odyssey protocol (LI-COR) was followed. The
fluorescence was quantified by Odyssey system (Li-COR). For
details of anti-mouse SREBP-2 polyclonal antibody (custom
antibody raised against mature SREBP-2 form [67]) and
immunoblot procedures, see Text S1.
Measurement of Free Cholesterol Concentration by
Enzymatic Assay
Intracellular cholesterol concentration was determined enzy-
matically using the Amplex-Red cholesterol Assay Kit (Molecular
Probes) according to manufacturer recommendations. Briefly, cells
were washed with 1 ml ice-cold PBS and then lysed in 200 ml cold
Lipid buffer containing 0.5 M of potassium phosphate, pH 7.4,
0.25 mM cholic acid, and 0.5% triton X-100. Cell lysates were
sonicated on ice with three 10-s pulses at high intensity. 20 ml were
then used to determine protein concentration using a standard
BCA assay to normalize the protein concentration. For cholesterol
measurement, 20 ml of each sample were added to the 80 ml assay
solution, which contained 300 mM Amplex Red reagent, 2 U per
ml HRP and 2 U per ml cholesterol oxidase, 0.1 M of potassium
phosphate, pH 7.4, 0.05 mM cholic acid, and 0.1% triton X-100.
After preincubation for 30 min at 37uC under light exclusion
conditions, fluorescence was measured using excitation at
53062.5 nm and fluorescence detection at 59062.5 nm with a
Polarstar Optima Multifunciton Microplate Reader (BMG
Labtech, UK). The values were corrected from the background.
The relative amount of free cholesterol to the mock-treated
samples was calculated using the manufacturer’s supplied standard
curve.
Analysis of Lipids Using High-Performance Liquid
Chromatography/Mass Spectrometry and Electrospray
Ionization
An Agilent high-performance liquid chromatography (HPLC)
system coupled with an Applied Biosystem Triple Quadrupole/
Ion Trap mass spectrometer (4000Qtrap) was used for quantifi-
cation of individual polar lipids (Phospholipids and sphingolipids).
Electrospray ionization-based multiple reaction monitoring
(MRM) transitions were set up for the quantitative analysis of
various polar lipids [68]. HPLC atmosphere chemical ionization/
MS were carried out for analysis of sterols [69].
Live Cell Replication Assay
To measure the effect of multiple drugs and siRNA transfection
on viral growth, a sensitive live cell infection assay was developed
using the properties of the mCMV GFP tagged virus. 1.56104
NIH/3T3 cells were infected for 1 h in black 96-well plates
(Costar, UK) at an MOI of 0.2 in 25 ml of fresh DMEM phenol
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red-free media, 3% CS, and 100 U of penicillin/streptomycin per
ml. After infection, the inoculums were carefully removed by
pipetting and replaced by 150 ml of DMEM phenol red-free media
with 10% FCS. Viral growth was measured by recording the GFP
signal over time using an OPTIMA Polarstar plate reader
(excitation wave length of 485 nm and emission of 520 nm). As
an optimization step we checked the correlation between GFP
levels and MOIs. Results showed a good correlation between
multiplicity of infection and growth kinetics (Figure S4). Compar-
ing the GFP value and number of viral particles per ml using
plaque assay checked levels of GFP signal corresponding to
different levels of virus. Results (unpublished data) showed a strong
correlation between differences in levels of GFP expression and
differences in number of viral particles assessed by plaque assay: a
drop of 20% of GFP signals corresponding to a log difference in
the number of viral particles monitored by plaque assay.
Transfection and siRNA Knock-Down Assays
For transfection, siRNA (SMARTpools-ON-TARGETplus
modification) from Thermo Fisher Inc. were purchased. The
samples were supplied at a concentration of 5 mM and diluted and
aliquoted in 2 mM amounts. To transfect at a final concentration
of 20 nM per well, 1 ml of siRNA SMARTpool was used with 9 ml
of Optimem (Invitrogen, CA, USA) solution while 0.4 ml of
Dharmafect 1 (Dharmacon, Perbio Science, Bonn, Germany) was
mixed with 9.6 ml Optimem. Following incubation for 5 min, the
siRNA mix was added to the Dharmafect 1 (0.4%) mix and
incubated for a further 30 min, after which 1.56104 NIH3T3 cells
in 80 ml of DMEM 10% CS medium lacking antibiotics was added
to the siRNA:Dharmafect 1 complexes. Growth medium was
removed and cells were washed 16 in PBS before 100 ml of the
siRNA: Dharmafect 1 liposomes were added. Transfection
conditions were optimized by using siGLO RED from Thermo
Fisher Scientific (Dharmacon) as an indicator of transfection
efficiency and cell viability was assessed as described before. For
every gene targeted, the knock-down efficiency was checked by
QPCR after 48 h incubation. Each of the three genes targeted
(Hmgcs1, Hgmcr, and Idi1) were knocked down by more than 70%,
48 h after transfection (Figure S5). Knock-down efficiency and cell
viability were also checked at 5 d post-infection for the mCMV-
GFP assay, and showed no alteration of the viability and a knock-
down efficiency $50% (unpublished data).
Nascent RNA Expression Profiling of TYK22/2 mCMV
Infected Macrophages Experiment
BMDM were isolated and grown in the presence of Csf1
derived from L929 cells as described [63] except cells were
cultivated in 15 cm diameter tissue culture plates for 7 d before
treatment. Incorporation of 4-thiouridine (Sigma) into nascent
RNA was undertaken as described [52]. In brief, at 360 min post-
infection, 10 ml medium was aspirated from all plates, added to
80 ml 4-Thiouridine, mixed, and immediately returned to the
culture dish. After 30 min, to end the RNA labeling period,
terminate transcription, and lyse the cells, medium was aspirated
from the labeled BMDM and replaced with 4 ml of RLT lysis
buffer (Qiagen). Total RNA was isolated using an RNeasy Midi kit
(Qiagen) according to the manufacturer’s instructions, quantitated
using a Nanodrop (Thermo Scientific), and integrity was
confirmed using an Agilent Bioanalyser (Agilent UK). Newly
transcribed RNA (ntRNA) was then isolated as described in [52]
and again quantitated using a Nanodrop.
Processing of ntRNA samples (94 ng) for hybridization to
Affymetrix Mouse Gene 1.0 ST arrays was undertaken according
to the manufacturer’s instructions (Affymetrix). Hybridisation,
washing, staining, and scanning of the arrays were also undertaken
following standard Affymetrix protocols. For the purposes of
presentation, gene expression values for the specific genes of
interest from control (mock-infected) BMDM were adjusted to a
value of 1. Values for expression in infected cells (white) were then
expressed as a number relative to the control.
In Vivo Studies
All animal experiments had approval by the local animal ethics
committee (University of Edinburgh, Edinburgh, UK) in accor-
dance with recommendations of the Federation of European
Animal Science Association and European legislation. Twelve
mice (C57/BL6, Charles River, 12 wk of age) were randomized
into two groups of six animals each in two separate experiments.
Simvastatin was prepared as described above. The dosages of
statins used in the present investigation were chosen according to
the literature [30]. At day 1, mice were inoculated i.p. with 26106
PFU per mouse. Animals were sacrificed 4 d post-infection.
Spleen, liver, kidney, heart, and lung were harvested and sonicated
as a 10% (wt/vol) tissue homogenate, and titers were determined
by standard plaque assays, including centrifugal enhancement of
infectivity on MEFp532/2. The dashed line indicates the limit of
detection (56102 PFU/g). Horizontal bars indicate the median
values.
Statistical Analysis
Normalization, filtering, statistical hypothesis testing for micro-
array data was carried out within the R Language and
Environment for Statistical Computing (www.r-project.org), using
packages provided through the Bioconductor repository (www.
bioconductor.org). The majority of explorative analyses and
visualizations were conducted with Partek (Partek Incorporated,
USA) and GeneSpring GX (Agilent). Statistical analyses on other
data sources were performed in Microsoft Excel software. For real-
time PCR and replication assay, all graphs represent the mean 6
SD. An unpaired Student’s t test was used for evaluation of
statistical significance of real-time PCR. For in vivo experiment a
Mann-Whitney U test was used. See Text S1 for statistical analysis
of microarray experiments. Statistical significance: *p,0.05,
**p,0.01, ***p,0.001.
Supporting Information
Figure S1 Pie chart representing the percentage of lipid class
present in (A): 62 down-regulated and 133 up-regulated Lipid
Associated Genes (LAGs) upon mCMV infection, (B) 51 down-
regulated and 65 up-regulated LAGs after IFNc treatment, and
(C) 35 down-regulated and 47 up-regulated LAGs by mCMV
infection and IFNc treatment.
Found at: doi:10.1371/journal.pbio.1000598.s001 (3.83 MB TIF)
Figure S2 Concentrations of four cholesterol synthesis-related
metabolites following mCMV infection. (A–D) Concentrations of
Zymosterol, 14-demethyl-lanosterol, 7-dehydro-cholesterol, and
free cholesterol are measured from lipid extract by MRM analysis
(Materials and Methods) from BMDM following mCMV infection
(MOI of 1 at 24 and 48 hpi). Bars represent means 6 SD of
triplicates biological measurements.
Found at: doi:10.1371/journal.pbio.1000598.s002 (0.31 MB TIF)
Figure S3 Lipidomic analysis using high performance liquid
chromatography/mass spectrometry and electroscopy ionization
of mCMV infected BMDM. Lipid analysis of total glyceropho-
spholipids (phosphatidylcholine, phosphatidylserine, phosphatidyl-
ethanolamine; A) and individual species of phosphatidylcholine (B)
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and phosphatidylserine (C) (Materials and Methods). Bars
represent means 6 SD of triplicates biological measurements.
Found at: doi:10.1371/journal.pbio.1000598.s003 (6.02 MB TIF)
Figure S4 Live cell mCMV-GFP growth curve. NIH3T3 were
infected at an MOI of 0.01, 0.1, and 1 with mCMV-GFP for 1 h,
and viral inoculums were replaced by fresh media. GFP signal was
measured at a different time post-infection (Materials and
Methods).
Found at: doi:10.1371/journal.pbio.1000598.s004 (0.09 MB TIF)
Figure S5 Knock-down efficiency. NIH3T3 cells were trans-
fected with 0.4% Dharmafect 1 and 25 nm of Hmgcs1, Hmgcr, or
Idi1 SiRNA smart pool (Dharmacon). After 48 h, RNA was
collected and QPCR was performed to check gene expression for
Hmgcs1, Hmgcr, and idi1. Gapdh was used for normalization.
Hmgcs1 shows an 81% decrease in expression following
transfection, Hmgcr a 70% decrease, and Idi1 an 82% decrease.
Bars represent means 6 SD of triplicate biological measurements.
Found at: doi:10.1371/journal.pbio.1000598.s005 (1.23 MB TIF)
Figure S6 mCMV infection reduced free intra-cellular choles-
terol in a dose-dependent manner in BMDM at 48 hpi. BMDM
were infected at different MOI (0, 0.1, 0.2, 0.5, and 1) with
mCMV virus. Data are represented as the percentage of free
intracellular cholesterol concentration from infected cells in
comparison to mock treatment. Results represent means 6 SD
from two independent experiments with triplicate biological
measurements for each experiment.
Found at: doi:10.1371/journal.pbio.1000598.s006 (1.32 MB TIF)
Figure S7 Effects of various concentrations of Simvastatin on
NIH-3T3 fibroblasts cell viability. NIH-3T3 fibroblasts were
treated with various concentrations of Simvastatin or with vehicle
for 72 h. Cell viability was determined using the Cell titre blue
assay as described in Methods. Cell viability is expressed as the
percentage of fluorescence signal from treated cells compared to
untreated cells. Graphs represent the average values (6SD) of two
independent experiments with triplicate biological measurements
for each experiment.
Found at: doi:10.1371/journal.pbio.1000598.s007 (0.04 MB TIF)
Figure S8
Found at: doi:10.1371/journal.pbio.1000598.s008 Specificity of
the SREBP2 antibody. Lane 1 and 2: Nuclear extract protein
prepared from livers of mice fed chow supplemented with either a
2% cholesterol diet (CHOL) or a mixture of lovastatin and
ezetimibe were loaded as controls. Arrow indicates the specific
SREBP2 cleaved form. As a comparison, lanes 3 and 4 show
nuclear protein extracts prepared from macrophages cultured
from mock or mCMV infected. YY1 protein was used as a loading
control. (1.36 MB TIF)
Table S1 List of lipogenic associated genes (LAGs) down- (A) or
up- (B) regulated by mCMV infection or down- (C) and up- (D)
regulated by IFNc treatment.
Found at: doi:10.1371/journal.pbio.1000598.s009 (0.09 MB XLS)
Table S2 Canonical pathway analysis. Analysis was performed
using IPA from Ingenuity (www.ingenuity.com): (A) 62 down-
regulated LAGs in response to mCMV infection, (B) 133 up-
regulated LAGs in response to mCMV infection, (C) 51 down-
regulated LAGs in response to IFNc treatment, (D) 65 up-
regulated LAGs in response to IFNc treatment, (E) 35 down-
regulated LAGS in response to mCMV infection and IFNc
treatment, and (F) 47 up-regulated LAGs in response to mCMV
infection and IFNc treatment. For each table, the top 5 most
significant pathways are represented.
Found at: doi:10.1371/journal.pbio.1000598.s010 (0.02 MB XLS)
Text S1 Supporting methods. This file gives an overview of the
methods used in this article.
Found at: doi:10.1371/journal.pbio.1000598.s011 (0.13 MB
DOC)
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